Back to UBS Group AG UBS Group AG

GALTGALT
Showing 8 of 27 quarters

Position history for UBS Group AGUBS Group AG's holdings in GALECTIN THERAPEUTICS INC

Yes. Ubs holds 219,319 shares of GALT (Galectin Therapeutics), worth $1M, as of its Q2 2026 13F filing. It increased the position by 39,578 shares (+22.0%) from Q1 2026. Ubs has held GALT since Q2 2024, across 9 quarterly 13F filings.

Current Value

$1M

Current Shares

219,319

Total Value Change

+$978,228

Total Shares Change

+204,987

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
219,319
+22.0%
$1M0.0%$4.64
30
2026-Q1
Increased
179,741
+359.6%
$501,4770.0%$2.79
39
2025-Q4
Increased
39,104
+24.1%
$162,6730.0%$4.16
19
2025-Q3
Decreased
31,514
-81.2%
$133,4610.0%$4.24
0
2025-Q2
Increased
167,865
+221.3%
$354,1960.0%$2.11
38
2025-Q1
Increased
52,244
+0.9%
$63,7390.0%$1.22
14
2024-Q4
Increased
51,780
+261.3%
$66,7960.0%$1.29
23
2024-Q3
Increased
14,332
+8.5%
$39,4130.0%$2.75
15

Other major holders of GALT: BlackRock, Inc., VANGUARD CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, OSAIC HOLDINGS, INC.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used